Allist In-Licenses ArriVent's First-in-Class MUC16×NaPi2b Bispecific ADC

China-based Allist Pharmaceuticals has signed a strategic agreement with ArriVent BioPharma granting Allist exclusive Greater China rights to research, develop, manufacture, register, and commercialise AST12608/ARR-002, a potential first-in-class tetravalent bispecific antibody-drug conjugate (ADC) targeting MUC16 and NaPi2b, initially in ovarian and endometrial cancers.

Preclinical data showed enhanced internalisation versus monospecific controls, superior efficacy in OVCAR-3 patient-derived xenograft models, and a wider therapeutic window in cynomolgus monkeys with only reversible haematologic changes at higher maximum tolerated doses. The asset cleared IND review in the US in May this year.

The deal extends a relationship that began in 2021 when Allist out-licenced furmonertinib ex-Greater China to ArriVent, with that molecule now in two global Phase III trials (FURVENT in EGFR exon 20 insertion, ALPACCA in EGFR PACC, the former holding Breakthrough Therapy status).

Daily News
BeiGene Advances its First ADC Into Phase III in Ovarian Cancer
2026-09-14
Zelgen's Becomes China's First PD-1×TIGIT BsAb in Phase III for Liver Cancer
2026-09-14
AZ, Amgen TCE+PD-L1 Combo Aces Phase III in Extensive-Stage SCLC
2026-09-11
Lumiere Closes Nine-Figure Pre-A Round for Epigenetic Editing Therapies
2026-09-11
Bayer's Sevabertinib Gains US Approval in First-Line HER2-Mutant NSCLC
2026-09-10
Latest Report
2026 TOP-25 Drug Targets
Details